Myelofibrosis

Support and Resources for Patients Taking Jakafi®


IncyteCARES PATIENT SUPPORT PROGRAM

IncyteCARES (Connecting to Access, Reimbursement, Education and Support) is designed to help eligible patients gain access to Jakafi®.


Graphic of hand and checkmark
Coverage Verification

We can check with a patient’s insurance plan about their coverage for Jakafi and any out-of-pocket costs required.

Graphic of a hand and Rx
Insurance Information

We can help patients understand how their insurance plan works and provide information about prior authorization requirements. We can also offer information about appealing insurance denials or restrictions.

Graphic of a mailbox
Delivery Coordination

An IncyteCARES nurse can locate a specialty pharmacy and help delivery of Jakafi directly to patients or their Healthcare Professional.

Graphic of a copay assistance card
Copay/Coinsurance Assistance

For patients with commercial or private insurance—eligible patients pay as little as $0 per month.*

Graphic of 2 patients
Patient Assistance Program (PAP)

Free product is offered to eligible patients who do not have prescription coverage for Jakafi.

Graphic of a calendar
Temporary Coverage

For insurance delays, eligible patients can receive a free supply of Jakafi.

Patient Education and Support

Through our call center, IncyteCARES registered nurses provide patients with continuing education and personalized support about their condition and Jakafi.

Connection to Other Support Services

For patients who aren’t eligible for assistance through IncyteCARES or who need additional support beyond what we can provide directly, our nurses can provide information to patients about other programs and resources, such as independent nonprofit organizations or foundations, that may be able to help.

*Amount of savings for the purchase of Jakafi will not exceed $11,977 per month and $25,000 per year. Uninsured, cash-paying patients are not eligible. Not valid for patients insured through Medicare Part D, Medicare Advantage, Medicaid, and TRICARE or any state medical or pharmaceutical assistance program. Valid prescription for Jakafi for an FDA-approved indication is required. Please see full criteria for eligibility below or call IncyteCARES. Update effective as of September 30, 2019.

Terms, conditions, and additional eligibility criteria apply. Valid prescription for Jakafi for an FDA-approved indication is required. Patients insured through Medicare Part D, Medicare Advantage, Medicaid, TRICARE, or a state medical assistance program are not eligible. Free product is offered to eligible patients without any purchase contingency or other obligation.

Some foundations or organizations may receive or have received donations from Incyte Corporation.


HOW TO ENROLL IN IncyteCARES

After you receive your prescription for Jakafi from your Healthcare Professional:
  • Call IncyteCARES at 1-855-4-Jakafi (1-855-452-5234)§
  • Answer a few simple questions to activate your copay/coinsurance card
  • Contact the pharmacy that is providing Jakafi and give them your card Group, Bin, and Member numbers to receive copay/coinsurance assistance for your prescription
Visit IncyteCARES to Learn More
Learn how Dan got the support he needed from IncyteCARES

Hear from Dan, a real patient taking Jakafi, as he explains how IncyteCARES helped him discover his path to possible.

§Pharmacies: Call 1-855-799-1295 to activate card.

connect-patient

Connect With
a Patient
Like Dan

Connect With a
Patient Like Dan

Register for the Incyte Mentor Program and connect with another patient taking Jakafi.

Email Address

Continue Registering

Expand Collapse

INDICATIONS AND USAGE

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is also used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: for certain types of MF and PV – low platelet or red blood cell counts, bruising, dizziness, and headache; and for acute GVHD – low platelet, red or white blood cell counts, infections, and fluid retention.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.